Amarin Decision Could Spur Pressure Against FDA On Supplement Claim Policy
This article was originally published in The Tan Sheet
First Amendment advocate Jonathan Emord says the industry bows to FDA “intimidation” in not making truthful claims for their products. But the federal district court ruling for Amarin is the latest decision to strike against FDA’s policy on regulating supplement label claims, he says.
You may also be interested in...
The trade group Global Organization for EPA and DHA Omega-3 petitions FDA for an unqualified health claim related to reduced blood pressure as a surrogate marker for coronary heart disease risk.
A court decision obligating FDA to reconsider a slate of qualified health claims for selenium could compel the agency to allow more QHCs for dietary supplements
CHPA members’ feedback on RRAs indicate that “time and resources saved by FDA do not translate to time saved by the manufacturer.” CRN suggests FDA “clearly identify the purpose of the RRA in its initial request and limit requested documents to only those directly related to the purpose of the RRA.”